SADDLEBROOK, N.J.–(BUSINESS WIRE)–Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, today announced the U.S. launch & commercial shipment of a generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg. Pregabalin Capsules had U.S. sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health.
Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. The product should be taken only as prescribed.
“The commercialization of Pregabalin Capsules is one of the largest volume launches for the company this year and will provide a cost effective treatment option for people living with debilitating neuropathic pain conditions,” said Vimal Kavuru, Chief Executive Officer for Rising Pharmaceuticals.
Rising Pharmaceuticals, as the exclusive distributor for its development and manufacturing partner, Laurus Labs Limited, who recently received final approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA), will launch the product immediately.
Rising is a leading supplier of generic medicines in the U.S., and the launch of Pregabalin Capsules, adds to the company’s robust and expanding human pharmaceutical franchise.
Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers. Currently, Rising has over 125 approved and commercial products in the US market and an additional 82 products pending launch or in development, representing a combined $12.5 billion in addressable market value. At Rising Pharmaceuticals, we continually seek out new opportunities to grow our business through strategic partnerships with developers, manufacturers and distributors under the Rising label.
Contacts
Margie Abrams, Corporate Communications, 210-961-9000